Mezagitamab clinical trials
Also written TAK-079.
How each study uses mezagitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mezagitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses mezagitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney TransplantRecruitingPhase 2TakedaNCT07613359Written as Mezagitamab
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingPhase 3TakedaNCT06722235Written as Mezagitamab
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingPhase 3TakedaNCT06963827Written as Mezagitamab
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingPhase 3TakedaNCT06948318Written as Mezagitamab
- A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background TherapyCompletedPhase 1TakedaNCT05174221Written as Mezagitamab
- A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)CompletedPhase 1TakedaNCT03984097Written as TAK-079
- A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune ThrombocytopeniaCompletedPhase 2TakedaNCT04278924Written as TAK-079
- A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)CompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03724916Written as TAK-079
- A Study of TAK-079 in People With Generalized Myasthenia GravisCompletedPhase 2TakedaNCT04159805Written as TAK-079
- A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)CompletedPhase 1/2Millennium Pharmaceuticals, Inc.NCT03439280Written as Mezagitamab
- A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy ParticipantsCompletedPhase 1TakedaNCT02219256Written as TAK-079
Given beside what is tested · 1 — mezagitamab is usual care or a partner of the new treatment
Codes
What other systems call mezagitamab · ClinicalTrials.gg INT014243
- UNII (FDA) 0XMR8L9LOLMEZAGITAMABOne source FDA
- NCI Thesaurus C148078MezagitamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0XMR8L9LOL | MEZAGITAMAB | One source FDA |
| NCI Thesaurus | C148078 | Mezagitamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.